Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 270 entries
View as:

A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT03745937 Org: User:
Start: 01/07/19 End: 05/28/19 Due: 05/28/20

A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma

Phase: N/A Priority: Normal
NCT ID: NCT00930683 Org: User:
Start: 09/30/09 End: 07/31/11 Due: 07/31/12

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

Phase: N/A Priority: Normal
NCT ID: NCT04068610 Org: User:
Start: 09/13/19 End: 10/10/22 Due: 10/10/23

A Phase 1, Single Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02394314 Org: User:
Start: 02/28/15 End: 08/31/15 Due: 08/31/16

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

Phase: N/A Priority: Normal
NCT ID: NCT03381274 Org: User:
Start: 05/08/18 End: 04/16/26 Due: 04/16/27

A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants

Phase: N/A Priority: Normal
NCT ID: NCT00192348 Org: User:
Start: 05/31/02 End: 12/31/02 Due: 12/31/03

Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months

Phase: N/A Priority: Normal
NCT ID: NCT00192166 Org: User:
Start: 10/31/02 End: 05/31/03 Due: 05/31/04

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Phase: N/A Priority: Normal
NCT ID: NCT00129766 Org: User:
Start: 11/30/04 End: 05/31/06 Due: 05/31/07

A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL)

Phase: N/A Priority: Normal
NCT ID: NCT00676871 Org: User:
Start: 06/30/08 End: 06/30/11 Due: 06/30/12

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

Phase: N/A Priority: Normal
NCT ID: NCT03611556 Org: User:
Start: 06/21/18 End: 07/22/22 Due: 07/22/23

A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well Tolerated

Phase: N/A Priority: Normal
NCT ID: NCT03550378 Org: User:
Start: 06/29/18 End: 02/04/19 Due: 02/04/20

Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT02525094 Org: User:
Start: 08/15/15 End: 07/15/16 Due: 07/15/17

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02519348 Org: User:
Start: 10/19/15 End: 03/31/25 Due: 03/31/26

A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide

Phase: N/A Priority: Normal
NCT ID: NCT04091373 Org: User:
Start: 09/27/19 End: 03/06/20 Due: 03/06/21

A Study to Assess Pharmacokinetics, Safety and Tolerability of Multiple Doses of CAT-354 in Subjects With Moderate Asthma

Phase: N/A Priority: Normal
NCT ID: NCT00974675 Org: User:
Start: 09/29/06 End: 08/03/07 Due: 08/03/08

Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age

Phase: N/A Priority: Normal
NCT ID: NCT00192140 Org: User:
Start: 06/30/04 End: 01/31/05 Due: 01/31/06

Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age

Phase: N/A Priority: Normal
NCT ID: NCT00493285 Org: User:
Start: 07/31/07 End: 04/30/10 Due: 04/30/11

Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024)

Phase: N/A Priority: Normal
NCT ID: NCT00240877 Org: User:
Start: 08/31/02 End: 04/30/04 Due: 04/30/05

Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT00192335 Org: User:
Start: 07/31/04 End: 02/28/05 Due: 02/28/06

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT01629667 Org: User:
Start: 10/31/12 End: 01/31/16 Due: 01/31/17

Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT00192517 Org: User:
Start: 12/31/03 End: 09/30/04 Due: 09/30/05

A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02318394 Org: User:
Start: 03/02/15 End: 01/09/18 Due: 01/09/19

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season

Phase: N/A Priority: Normal
NCT ID: NCT02473510 Org: User:
Start: 06/30/15 End: 01/31/16 Due: 01/31/17

A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT01706926 Org: User:
Start: 08/31/12 End: 01/31/14 Due: 01/31/15

A Post Marking Study to Evaluate the Safety of FluMist in Children

Phase: N/A Priority: Normal
NCT ID: NCT00569894 Org: User:
Start: 10/31/07 End: 06/30/11 Due: 06/30/12